21 December 2015
IXICO PLC
("IXICO" or the "Company")
Update on Issued Share Capital
21 December 2015: Further to the completion of the acquisition of Optimal Medicine on 8 December 2015 IXICO plc (AIM: IXI) today announces that one of the vendors of Optimal Medicine subsequently gave up their entitlement to 2,168 Completion Consideration Shares which have therefore been cancelled. Accordingly the Company's issued share capital is 26,443,418 Ordinary Shares which are admitted to trading on AIM. Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular dated 18 November 2015.
For further information, please contact:
IXICO plc |
Tel: +44 (0) 20 3763 7499 |
Derek Hill, CEO |
|
Susan Lowther, CFO |
|
Charles Spicer, VP Corporate Development |
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
Tel: +44 (0) 20 7418 8900 |
James Steel |
|
Oliver Jackson |
|
|
|
FTI Consulting Limited (Investor Relations) |
Tel: +44 (0) 20 3727 1000 |
Simon Conway |
|
Mo Noonan |
|
Matthew Moss |
|
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com
